| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022020034 |
| P356 | DOI | 10.1007/S12975-010-0018-4 |
| P932 | PMC publication ID | 2881325 |
| P698 | PubMed publication ID | 20539748 |
| P5875 | ResearchGate publication ID | 44665192 |
| P2093 | author name string | Paul A Lapchak | |
| P2860 | cites work | Effectiveness and safety of transcranial laser therapy for acute ischemic stroke | Q33411238 |
| Neuroprotective effect of volatile anesthetic agents: molecular mechanisms | Q33419745 | ||
| Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5'-triphosphate (ATP) content following embolic strokes in rabbits | Q33511153 | ||
| Thrombolysis in acute ischemic stroke: controlled trials and clinical experience | Q33758215 | ||
| Newer thrombolytic agents | Q33781151 | ||
| Recommendations for standards regarding preclinical neuroprotective and restorative drug development | Q33785562 | ||
| Use of the Barthel index and modified Rankin scale in acute stroke trials. | Q33870093 | ||
| Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke | Q33991631 | ||
| Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. | Q33997543 | ||
| Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. | Q34148131 | ||
| Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. | Q34458794 | ||
| Development of thrombolytic therapy for stroke: a perspective | Q35001038 | ||
| NXY-059. Centaur. | Q35045247 | ||
| Animal models of focal and global cerebral ischemia | Q35090269 | ||
| Models of focal cerebral ischemia in the nonhuman primate | Q35090273 | ||
| The ischemic penumbra: identification, evolution and treatment concepts | Q35615678 | ||
| Stroke--incidence, mortality, morbidity and risk. | Q35858899 | ||
| Neuroprotective effects of anesthetic agents | Q36116964 | ||
| Brain protection by anesthetic agents | Q36588946 | ||
| Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. | Q36810934 | ||
| Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke | Q36853648 | ||
| The need for animal models in small-vessel brain disease | Q36921581 | ||
| Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance | Q37034277 | ||
| Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. | Q37301824 | ||
| Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. | Q37436384 | ||
| Potential animal models of lacunar stroke: a systematic review | Q37457707 | ||
| tPA in acute ischemic stroke: United States experience and issues for the future | Q38476791 | ||
| Evaluation of recombinant tissue plasminogen activator in embolic stroke | Q39273382 | ||
| Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit | Q39290725 | ||
| NIHSS training and certification using a new digital video disk is reliable | Q39732943 | ||
| Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators | Q40791071 | ||
| NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species | Q43515003 | ||
| NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. | Q43691614 | ||
| Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia | Q43820256 | ||
| Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator | Q43978719 | ||
| Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. | Q44064251 | ||
| Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke | Q44090679 | ||
| Rodent models of focal stroke: size, mechanism, and purpose | Q24529165 | ||
| Effects of NXY-059 in experimental stroke: an individual animal meta-analysis | Q24654761 | ||
| Pathobiology of ischaemic stroke: an integrated view | Q28141682 | ||
| NXY-059 for acute ischemic stroke | Q28296316 | ||
| Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q28303699 | ||
| Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window | Q28344856 | ||
| Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke | Q29619330 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis | Q30664838 | ||
| Thrombolytic therapy for ischemic stroke--a review. Part II--Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging | Q30664853 | ||
| Imaging the penumbra in acute stroke | Q31047955 | ||
| Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. | Q31064287 | ||
| Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. | Q31113573 | ||
| Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke | Q31882987 | ||
| Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model | Q33217880 | ||
| Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain | Q33255855 | ||
| Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits | Q33256018 | ||
| Advances in ischemic stroke treatment: neuroprotective and combination therapies | Q33278117 | ||
| Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). | Q33282974 | ||
| Global and regional brain metabolic scaling and its functional consequences | Q33284074 | ||
| Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures | Q44413927 | ||
| Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters | Q44418044 | ||
| Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion | Q44550693 | ||
| Strengthening acute stroke trials through optimal use of disability end points | Q44621059 | ||
| The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model | Q44629305 | ||
| Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion | Q44921869 | ||
| Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores | Q44972756 | ||
| Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? | Q46036811 | ||
| Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits | Q46162153 | ||
| The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator | Q46318985 | ||
| The novel antioxidant edaravone: from bench to bedside | Q46591722 | ||
| Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction | Q46616411 | ||
| NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials | Q46680379 | ||
| Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model | Q46744429 | ||
| Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia | Q46920755 | ||
| Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes | Q46971675 | ||
| Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model | Q48127557 | ||
| Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging | Q48155636 | ||
| Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. | Q48158692 | ||
| Efficacy of edaravone in cardioembolic stroke | Q48593468 | ||
| Edaravone in acute ischemic stroke | Q48593479 | ||
| Penumbra is brain: no excuse not to perfuse | Q48721546 | ||
| Ischemic stroke subtypes: a population-based study of incidence and risk factors. | Q50654471 | ||
| Tissue plasminogen activator reduces neurological damage after cerebral embolism. | Q53986915 | ||
| Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) | Q55063586 | ||
| Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology | Q60652059 | ||
| Delayed Tissue-Plasminogen Activator Therapy in a Rabbit Model of Thromboembolic Stroke | Q71980701 | ||
| Effect of hypothermia and delayed thrombolysis in a rat embolic stroke model | Q72360621 | ||
| Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study | Q73288997 | ||
| Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study | Q73513390 | ||
| Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats | Q73563868 | ||
| The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators | Q73643427 | ||
| Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke | Q73718399 | ||
| Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence | Q73746614 | ||
| tPA-associated reperfusion after acute stroke demonstrated by SPECT | Q74212346 | ||
| [Experimental models of cerebral ischemia] | Q79662320 | ||
| NXY-059 for the treatment of acute ischemic stroke | Q80768385 | ||
| Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model | Q81920376 | ||
| P433 | issue | 2 | |
| P921 | main subject | embolic stroke | Q107538662 |
| P304 | page(s) | 96-107 | |
| P577 | publication date | 2010-04-02 | |
| P1433 | published in | Translational stroke research | Q26842494 |
| P1476 | title | Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development | |
| P478 | volume | 1 |
| Q35243300 | A blinded, randomized study of L-arginine in small clot embolized rabbits |
| Q35175537 | A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy |
| Q33938450 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? |
| Q42222232 | A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits |
| Q34901610 | Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles? |
| Q39558507 | CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut |
| Q36097037 | Clinical neuroprotective drugs for treatment and prevention of stroke |
| Q42740211 | Continuous monitoring of changes in plasma nitrite following cerebral ischemia in a rabbit embolic stroke model |
| Q36056147 | Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. |
| Q38681976 | De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays |
| Q43165001 | Deep-tissue oxygen monitoring in the brain of rabbits for stroke research |
| Q34417300 | Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke |
| Q38088270 | Development of transcranial sonothrombolysis as an alternative stroke therapy: incremental scientific advances toward overcoming substantial barriers |
| Q36841904 | Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules |
| Q47912292 | Dynamic EPR Oximetry of Changes in Intracerebral Oxygen Tension During Induced Thromboembolism |
| Q34432486 | Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke. |
| Q55281571 | Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model. |
| Q41908695 | Embracing Biological and Methodological Variance in a New Approach to Pre-Clinical Stroke Testing |
| Q35029799 | Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims |
| Q34164787 | Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! |
| Q37420266 | Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. |
| Q34294669 | Improving the translation of animal ischemic stroke studies to humans. |
| Q34433111 | J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox(™) Safety and Genotoxicity Analysis |
| Q34339125 | Near-infrared laser treatment of acute stroke: from bench to bedside |
| Q37821005 | Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective |
| Q35589930 | Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia |
| Q36816551 | RIGOR guidelines: escalating STAIR and STEPS for effective translational research |
| Q27024324 | Recommendations for preclinical research in hemorrhagic transformation |
| Q33930564 | Resolving the negative data publication dilemma in translational stroke research |
| Q37527216 | Scientific Rigor Recommendations for Optimizing the Clinical Applicability of Translational Research |
| Q33976397 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator |
| Q48331925 | Sisyphus and translational stroke research |
| Q51838409 | Stroke Cytoprotection: Can Repeating History with New Expectations Really Be the Path to Success in Stroke Research? |
| Q37284566 | Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits |
| Q33734891 | Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science |
| Q26852140 | The use of animal models for stroke research: a review |
| Q30370528 | Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke. |
| Q34092740 | Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. |
| Q50679562 | Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection. |
Search more.